A Therapy for NASH, Another Alzheimer's Competitor, and Reflections on 2022

Biotech Bros

English - January 02, 2023 13:00 - 1 hour - 43 MB
Investing Business Health & Fitness Medicine biotech investing money finance get rich markets comedy health healthcare Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Questions around the Tesla of Biotech, Amgen buying Horizon, and Mirati in the Dumps

Next Episode: The Importance of Value Perception in Biotech with Samina Bari

This week on the podcast Agustin discusses Madrigal Pharmaceuticals' recent phase III win in NASH, he highlights another monoclonal antibody in the Alzheimer's space, and provides a reflection on the markets in 2022.

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

Twitter Mentions

@biotech_bros